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PREVIOUS studies using adenoviral vectors in experi-
mental liver transplant settings have demonstrated in 
vivo infectivity by perfusing grafts with viral vectors. 1•2 
However. these techniques required high viral titers (1 to 
5 X 1010 plaque-forming units [pfu)) to induce effective 
viral infection. In this study, we developed an improved 
gene delivery method that allows near maximal infectivity 
of adenoviral vector to liver grafts by trapping vector 
perfusate within the graft for the duration of the cold 
preservation period. Using this technique. we successfully 
delivered an adenovirus encoding the human inducible 
nitric oxide synthase (iNOS) gene to cold-preserved liver 
grafts. Nitric oxide (NO) has been shown to have protective 
properties.3 due to its vasoprotective, antiinflammatory and 
antiapoptotic effects and its activity as a free radical scav-
enger. We therefore hypothesized that delivery of the iNOS 
gene to liver grafts will decrease ischemic damage in the 
early posttransplant period. 
METHODS 
Plaque-forming units (1 x 109 ) (multiplicity of infection [MOl) 0.4) 
of adenovirus encoding the LacZ gene (AdLacZ, GenVec. Rock-
ville. Md) were delivered to cold-preserved rat liver grafts by three 
dilIerent methods: (I) continuous perfusion via the portal vein 
(portal perfusion); (2) continuous perfusion via both the portal 
vein and hepatic artery (dual perfusion); and (3) trapping of viral 
perfusate in the liver vasculature by clamping outflow (clamp 
technique). Control animals were perfused without viral vector. 
LacZ gene expression was detected by X-gal staining (expressed as 
percent positive cells), and by t3-galactosidase enzyme assay (ex-
pressed as (3-gal activity per total protein [U/g)). Using the delivery 
method providing the highest infectivity. duration of gene expres-
sion and associated liver injury were analyzed by killing animals at 
1. 2. 7. 14, and 28 days posttransplant (n = 3 at each timepoint). 
Livers from control and experimental animals were stained with 
hematoxylin-eosin and evaluated for damage and inflammation. 
Adenovirus encoding the human iNOS gene (AdiNOS. GenVec) 
was delivered to liver grafts using the clamp technique at a titer of 
2 x 108 pfu. Animals were killed 48 hours posttransplant. The 
presence of iNOS mRNA in transplanted livers was analyzed by 
reverse transcriptase polymerase chain reaction (RT-PCR) and 
protein production was examined by immunohistochemistry using 
the polyclonal rabbit antihuman iNOS antibody NOS3 (a gift from 
Merck & Co. Rahway. NJ). 
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RESULTS 
Using 1 X 109 pfu AdLacZ (MOl 0.4). the transduction rate 
in 3-hour-preserved liver grafts 48 hours posttransplant was 
greatest with the clamp technique (21.5 :!: 2.7% X-gal-
positive cells and 81.1 :!: 3.6 U/g l3-gal activity, P < 0.01 vs 
portal perfusion), followed by dual perfusion (18.5 :!: 1.8%, 
66.6 :!: 19.4 U/g, P < .01 vs portal perfusion) and portal 
perfusion (8.8 :!: 2.5%, 19.7 :!: 15.4 U/g). Further studies 
using the clamp technique demonstrated a near maximal 
gene transfer rate (29.9 :!: 5.1 %, 109.6 :!: 6.9 U/g) at MOl 
0.4 with prolonged cold preservation to 18 hours. LacZ 
expression using the clamp technique was stable for 2 weeks 
and slowly declined to 7.8 :!: 12.1% and 40.1 :!: 49.4 U/g at 
day 28. Lack of an inflammatory response to the viral vector 
was confirmed by histopathologic examination. Liver en-
zymes peaked at 12 to 24 hours, but quickly normalized 
within 3 days posttransplant in both experimental and 
control animals. Gene transduction was induced selectively 
in hepatocytes with nearly no extrahepatic transgene ex-
pression in the lung and spleen. In AdiNOS-transduced 
livers, tissues stained with antihuman iNOS antibody demon-
strated a transduction rate similar to that seen in AdLacZ-
transduced livers. The presence of iNOS mRNA in AdiNOS-
transduced livers was confirmed by RT-PCR analysis. 
DISCUSSION 
In this study, we demonstrated a highly efficient adenoviral 
gene delivery method to cold-preserved liver grafts that 
offers maximal infectivity with minimal technical manipula-
tion. In the clamp technique, vector infusion via both the 
portal vein and hepatic artery allows delivery of viral vector 
to areas of microcirculation that are inaccessible by single 
perfusion, and vector-target cell contact is enhanced by 
trapping of vector in the liver microcirculation, likely ac-
counting for the superior infectivity using this technique. 
The lack of an inflammatory response in this study may be 
related to the fact that transduction was limited almost 
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exclusively to hepatocytes. with little expression in non-
parenchymal cells and extrahepatic tissue. The viral pro-
teins and the transgene may therefore be sequestered from 
the recipient immune system. The eventual loss of trans-
gene expression is not clear. but may be due to silencing of 
the CMV promoter.4 Finally. we have shown initial feasi-
bility of adenoviral-mcdiated iNOS gene delivery. Studies 
are underway to investigate the effects of iNOS gene 
delivery in liver and other solid-organ transplants. 
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